Harmony Gold Mining Co. vs Nuvalent Inc — how do they compare? Harmony Gold Mining Co. trades at $15.88 (market cap $9.48B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Harmony Gold Mining Co. and Nuvalent Inc are close in size by market cap, and Harmony Gold Mining Co. pays a 2.66% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| HMY | NUVL | |
|---|---|---|
Market Cap | $9.48B | $9.81B |
Sector | Basic Materials | Technology |
52-Week High | $26.04 | $123.96 |
52-Week Low | $12.61 | $72.16 |
Enterprise Value | $9.82B | $8.52B |
Dividend Yield | 2.66% | — |
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $15.325, up 4.61% today, but technical indicators signal a bearish trend with key resistance at $15. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, yet recent earnings missed expectations. Cash flow from operations improved to $15.65B in 2024, though 2025 projections show a net cash outflow. Analyst sentiment is mixed, with 70% hold ratings, reflecting caution amid gold price volatility and Fed rate hike concerns.
The outlook for HMY hinges on gold and copper price stability, with operational execution critical. Investment opportunities include a low P/E of 9.17 and a 4.06% dividend yield, but risks involve earnings misses, rising costs, and macroeconomic pressures. Investors should weigh strong profitability against sector headwinds and analyst skepticism.
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
Trailing returns across standard periods
Latest headlines on both assets
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →